Molecular Weight: 5136 g/mol
What is Tesamorelin?
There are 44 amino acids in the human Growth Hormone Releasing Hormone’s 44 amino acid sequence that go into tesamorelin, giving it its unique properties.
To treat HIV-infected individuals with lipodystrophy, researchers developed tesamorelin, a synthetic peptide counterpart of the hypothalamic peptide (GHRH). As a side effect of HIV antiretroviral treatment, lipodystrophy is characterized by insulin tolerance, fat distribution, and hyperlipidemia.
Tesamorelin differs somewhat from growth hormone-releasing hormone (GHRH) in that its N-terminal amino acid part has been changed for better stability and pharmacodynamics.
Subjects with HIV-related changes in the distribution of body fat may benefit from the use of tesamorelin to decrease belly fat. Tesamorelin shall not be utilized to treat obesity or to aid in weight reduction.
Cancer, pituitary gland problem, or past pituitary gland tumors are contraindications to using Tesamorelin. Also, prior head trauma or radiation therapy are contraindications as well.
Mechanism of Action
When taken, Tesamorelin increases the body’s production of growth hormone, which helps the substance operate. Tesamorelin stimulates the generation and release of endogenous hormones from pituitary units in the hippocampus (hGRF). Tesamorelin boosts IGF-1 and IGFBP-3 levels by stimulating growth hormone release.
Because tesamorelin replicates the function of an organic hormone, it also has an effect on certain target organs and tissues. As a result, tesamorelin’s mode of action is very specialized.
Tesamorelin binds to the anterior pituitary gland’s growth hormone-releasing hormone transmitters (GHRHr). This ligand binds to growth hormone receptors in the pituitary gland, causing the growth hormone receptors to release (GH).
Adipocytes (adipose units), hepatocytes (liver cells), myocytes (muscle cells), and osteoblasts are the primary targets of growth hormone (GH) (bone cells).
As a safety measure, a strong feedback mechanism is activated to keep the tesamorelin-induced secretion of growth hormone (GH) within predetermined limits.
Tesamorelin, by spontaneously triggering the secretion of growth hormone (GH), keeps the Hypothalamus and pituitary gland in homeostatic balance.
Effects of Using This Product
Tesamorelin’s adverse effects, when present, are generally moderate. However, the following negative effects may occur: soreness and bruises at the injection site; redness and irritation; depression; sleeplessness; rash or itching; night sweats; nausea; and/or vomiting are all possible side effects.
- An increase in the natural synthesis of human growth hormone
- An increase in IGF-1 and IGFBP-3 levels has been seen.
- Lowering of triglyceride levels
- More protein is synthesized
- Reduction of visceral fat
- Subjects over 60 years of age benefit from improved cognition.
- Reduce inflammatory markers
- A reduction in belly fat
Tesamorelin also improved measurements of body composition by lowering trunk fat, waist diameter, and waist-to-hip ratio.
This drug has also been shown to shrink the carotid intima-media, which is good news for your heart! (cIMT). As a result, carotid atherosclerotic vascular illness development is slowed.
Someday, these positive outcomes may help prove a connection between the use of tesamorelin medication and lower rates of cardiovascular disease.
Insulin-like growth factor 1 levels are reduced in lipodystrophic patients (IGF-1). When given tesamorelin, the liver’s hepatocytes produce (IGF-1) in response. IGF-7 promotes cell proliferation while inhibiting the mechanism of programmed cell death without affecting blood glucose levels.
Tesamorelin performs lipolysis, which lowers cholesterol and triglyceride levels. As a result, those who received tesamorelin saw an improvement in their lipid profiles. If any of the results mentioned above are interesting to you, then you can find peptides for sale with a credit card and further study them for research purposes only.